🔎 Trials Near Me

Dachaigh › Myeloma iomaill › Connecticut › New Haven

Sgrùdaidhean clionaigeach Myeloma iomaill ann an New Haven, CT

Tha 14 sgrùdaidhean airson Myeloma iomaill a’ lorg phàirtichean aig làraichean ann agus timcheall air New Haven (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.

Teacsa sgrùdaidh oifigeil (Beurla)

A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

A’ fastadhÌre 1
  • Yale University, New Haven
  • Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mìle air falbh
  • Smilow Cancer Hospital-Derby Care Center, Derby · 8 mìle air falbh
  • agus 1 a bharrachd
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT06465316

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

A’ fastadhÌre 3
  • Yale Cancer Center, New Haven
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07258511

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

A’ fastadhÌre 2
  • Yale University School Of Medicine, New Haven
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06500884

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

A’ fastadhÌre 1/2
  • Smilow Cancer Center At Yale-New Haven /ID# 272447, New Haven
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT06953960

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

A’ fastadhÌre 3
  • Yale University, New Haven
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Sult 2026 · NCT07555938

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

A’ fastadhÌre 1/2
  • Yale New Haven Hospital-Smilow Cancer Center, New Haven
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Sult 2026 · NCT06988488

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

A’ fastadhÌre 3
  • Smilow Cancer Center/Yale-New Haven Hospital, New Haven
  • Yale University, New Haven
  • Smilow Cancer Hospital-Orange Care Center, Orange · 5 mìle air falbh
  • agus 3 a bharrachd
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 19 Lùna 2026 · NCT04566328

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

A’ fastadhÌre 3
  • Research Site, New Haven
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Lùna 2026 · NCT07764978

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

A’ fastadhÌre 3
  • Smilow Cancer Center/Yale-New Haven Hospital, New Haven
  • Yale University, New Haven
  • Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mìle air falbh
  • agus 2 a bharrachd
Gach aois · Gach gnè · Air ùrachadh 10 Ògmh 2026 · NCT05561387

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

A’ fastadhÌre 2
  • Yale University, New Haven
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 13 Cèit 2026 · NCT06993675

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

A’ fastadhÌre 1
  • Yale Cancer Center, New Haven
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Màrt 2026 · NCT06153251

Sgrùdaidhean Myeloma iomaill ann am bailtean eile

Sgrùdaidhean eile ann an New Haven

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.